MONAT and hair loss have become closely linked topics online, with numerous users reporting increased shedding and scalp irritation after using the brand's haircare products. Understanding whether MONAT products can genuinely cause hair loss requires careful consideration of the evidence, the many common causes of alopecia, and how cosmetic ingredients interact with individual scalp health. This article examines what is currently known, how UK regulations apply, when to seek medical advice, and what NHS-recommended treatments are available for hair loss — helping you make informed decisions about your hair and scalp health.

Can MONAT Products Cause Hair Loss?

No formal regulatory action has been taken against MONAT products in the UK, and consumer complaints alone do not establish causation; individual adverse reactions are possible and should be reported to OPSS via GOV.UK.

Experiencing these side effects? Our pharmacists can help you navigate them →

MONAT is a US-based haircare brand that markets a range of shampoos, conditioners, and scalp treatments, primarily through a direct-sales model. A number of users have reported experiencing increased hair shedding, scalp irritation, and changes in hair texture after using MONAT products, and these reports have prompted questions about whether the products themselves may be responsible.

It is important to approach this topic with caution and balance. Consumer complaints, while valid experiences worth taking seriously, do not on their own constitute clinical evidence of causation. Hair loss is an extremely common condition with a wide range of potential triggers, and attributing it to a single product requires careful consideration of individual circumstances, timing, and other contributing factors.

In the UK, cosmetic products — including haircare ranges — are regulated under the UK Cosmetics Regulation (retained EU Regulation (EC) No 1223/2009), overseen by the Office for Product Safety and Standards (OPSS). To date, no formal regulatory action has been taken by OPSS against MONAT products in the UK. The absence of regulatory action does not confirm that a product is safe for every individual user; post-market surveillance of cosmetics continues through the OPSS serious undesirable effects (SUE) reporting system.

If you experience an adverse reaction to a cosmetic product such as a shampoo or scalp treatment, you should report this to OPSS via the 'Report a serious undesirable effect to a cosmetic product' portal on GOV.UK, and notify the product's Responsible Person. If you suspect an adverse reaction to a medicine or medical device, use the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. This distinction is important: the Yellow Card scheme is not the appropriate route for cosmetic product reactions.

Understanding Hair Loss: Common Causes and Triggers

Hair loss has numerous causes including androgenetic alopecia, telogen effluvium, nutritional deficiencies, and medication side effects, making it essential to assess all contributing factors before attributing shedding to any single product.

Not sure if this is normal? Chat with one of our pharmacists →

Hair loss — medically referred to as alopecia — is a widespread condition affecting both men and women across all age groups. Understanding its many potential causes is essential before attributing shedding to any particular product. The most common form is androgenetic alopecia (pattern baldness), which is largely driven by genetic and hormonal factors. However, numerous other triggers can cause temporary or permanent hair loss.

Some of the most frequently identified causes include:

• Telogen effluvium: A temporary form of diffuse shedding often triggered by physical or emotional stress, illness, hormonal changes (such as those following pregnancy or thyroid dysfunction), or significant dietary changes. Importantly, shedding typically begins with a latency of around 2–3 months after the triggering event, which can make it difficult to identify the cause.

• Alopecia areata: An autoimmune condition causing patchy hair loss.

• Traction alopecia: Caused by prolonged tension on the hair from tight hairstyles.

• Nutritional deficiencies: Iron deficiency and thyroid disease have the strongest evidence base for an association with hair shedding. Associations with low vitamin D or zinc levels have been reported but the evidence is inconsistent; testing should be guided by clinical suspicion and individual risk factors rather than routine supplementation.

• Scalp conditions: Seborrhoeic dermatitis, psoriasis, or fungal infections can disrupt the hair growth cycle.

• Medication-induced alopecia: A number of commonly prescribed medicines — including anticoagulants, retinoids, and certain antihypertensives — are recognised causes of drug-induced hair loss.

It is also worth noting that the average person naturally sheds between 50 and 100 hairs per day as part of the normal hair growth cycle. Periods of increased shedding can feel alarming but may reflect a delayed response to a stressor that occurred weeks or months earlier. This complexity makes it genuinely difficult to isolate a single cosmetic product as the definitive cause of hair loss without thorough clinical assessment. NICE Clinical Knowledge Summaries (CKS) and the Primary Care Dermatology Society (PCDS) provide structured guidance for the assessment of hair loss in primary care.

Ingredients in MONAT Products and Scalp Health

MONAT products contain ingredients such as behentrimonium methosulphate and fragrance compounds that are generally safe but can cause contact dermatitis in sensitive individuals, potentially contributing to temporary hair shedding.

MONAT markets its products as being free from sulphates, parabens, and certain other commonly avoided cosmetic ingredients. The brand promotes a proprietary blend it calls Rejuveniqe Oil, which contains a mixture of plant-derived oils and botanical extracts. While these ingredients are generally considered safe for cosmetic use at permitted concentrations, individual responses to any formulation can vary considerably depending on scalp sensitivity, pre-existing skin conditions, and allergic predispositions.

Some ingredients found in MONAT products have attracted scrutiny from consumers. For example, certain formulations contain behentrimonium methosulphate, a conditioning agent that, while generally regarded as mild, can cause irritation in sensitive individuals. Fragrance compounds — present in many haircare products — are a well-recognised cause of contact dermatitis and scalp sensitivity, and are among the most common cosmetic allergens identified in patch testing.

It is important to emphasise that most cosmetic ingredients are safe for the majority of users at the concentrations used in licensed formulations. However, contact dermatitis of the scalp — whether irritant or allergic in nature — can disrupt the hair follicle environment and, in some cases, contribute to temporary hair shedding. If a product causes significant scalp inflammation, this could theoretically precipitate a localised telogen effluvium. This would be expected to resolve once the offending product is discontinued and any inflammation is treated.

Anyone suspecting a product-related scalp reaction should stop use immediately and seek advice from a GP or dermatologist. Patch testing, carried out by a dermatologist, can help identify specific ingredient sensitivities. The British Association of Dermatologists (BAD) and the NHS provide patient-facing information on contact dermatitis and available assessment pathways.

What the Evidence Says About MONAT and Hair Shedding

No peer-reviewed clinical studies have directly investigated a causal link between MONAT products and hair loss; available information is largely limited to consumer testimonials and legal complaints, which cannot establish causation.

The scientific evidence specifically examining MONAT products and hair loss is extremely limited. There are no peer-reviewed clinical studies published in reputable medical journals that have directly investigated a causal relationship between MONAT haircare products and hair shedding or scalp damage. The majority of available information comes from consumer testimonials, online forums, and legal complaints — sources that, while informative, carry significant limitations in terms of scientific rigour.

It is important to understand that spontaneous adverse event reports — whether submitted to regulators or shared on consumer platforms — cannot establish causation. They are useful for generating safety signals that regulators can investigate further, but they do not confirm that a product caused a particular outcome.

In the United States, MONAT faced civil litigation in which plaintiffs alleged that the products caused hair loss and scalp damage. The company denied these claims. This legal context has limited direct relevance to UK clinical practice or regulation, and should not be interpreted as evidence of causation.

Reviews of MONAT's publicly available ingredient lists have not identified ingredients that are inherently known to cause hair loss at concentrations typically used in cosmetic products. This does not mean that individual adverse reactions are impossible or should be dismissed. Cosmetic products can cause idiosyncratic reactions in susceptible individuals, and the absence of large-scale evidence does not equate to proof of safety for every user.

If you have experienced hair changes after using any new haircare product, documenting the timeline carefully and discussing this with a healthcare professional will help determine whether the product is a plausible contributing factor or whether another underlying cause warrants investigation.

When to See a GP or Dermatologist About Hair Loss

You should see a GP if hair loss is sudden, patchy, rapidly progressive, or accompanied by scalp symptoms such as pain or redness, as these may indicate a treatable or scarring condition requiring urgent review.

Hair loss that is sudden, patchy, rapidly progressive, or accompanied by other symptoms should always be assessed by a healthcare professional. Whilst some degree of shedding is entirely normal, certain patterns of hair loss may indicate an underlying medical condition that requires diagnosis and treatment.

Prompt assessment is particularly important if hair loss is accompanied by scalp pain, burning, persistent redness, or visible changes such as a shiny scalp surface, loss of follicular openings, or tufting of hairs — features that may suggest scarring (cicatricial) alopecia, which requires urgent dermatological review as it can cause permanent follicle damage if untreated.

You should consider contacting your GP if you notice:

• Sudden or rapid hair loss over a short period of time

• Patchy bald areas on the scalp, beard, or eyebrows

• Diffuse thinning across the whole scalp

• Scalp symptoms such as persistent itching, soreness, flaking, or inflammation

• Hair loss accompanied by fatigue, weight changes, or other systemic symptoms that may suggest thyroid dysfunction or nutritional deficiency

• Hair loss that began shortly after starting a new medication, as many drugs — including anticoagulants, retinoids, and certain antihypertensives — are known to cause drug-induced alopecia

• Any features suggestive of scarring alopecia as described above, which warrants urgent referral

If you suspect a cosmetic product has caused or worsened your hair loss, discontinue use and report the reaction via the OPSS 'Report a serious undesirable effect to a cosmetic product' portal on GOV.UK. Your GP may refer you to an NHS dermatologist for further assessment, which may include trichoscopy, scalp biopsy, or blood tests to rule out systemic causes. NICE CKS and PCDS guidance support structured assessment and referral pathways in primary care.

NHS-Recommended Treatments for Hair Loss in the UK

Treatment depends on the underlying cause; options include over-the-counter minoxidil for androgenetic alopecia, prescription finasteride for men, and NICE-approved baricitinib for severe alopecia areata, all requiring accurate diagnosis first.

The appropriate treatment for hair loss depends entirely on its underlying cause, which is why accurate diagnosis is the essential first step. NICE guidelines and NHS clinical pathways support a structured approach to investigating and managing alopecia, tailored to the individual's pattern of hair loss, medical history, and preferences.

For androgenetic alopecia (the most common form), the following options are recognised:

• Minoxidil (available over the counter as Regaine® in the UK): A topical solution or foam applied directly to the scalp. It is thought to prolong the anagen (growth) phase of the hair cycle and improve follicular blood supply. It is available for both men and women, though formulations and licensed indications differ — refer to the relevant Summary of Product Characteristics (SmPC) or BNF entry for dosing guidance. Important safety points: an initial increase in shedding during the first few weeks of use is common and does not indicate treatment failure. Local scalp reactions (irritation, dryness, or contact dermatitis) can occur. Minoxidil should be avoided during pregnancy and breastfeeding; consult your GP or pharmacist before use if you have any cardiovascular conditions.

• Finasteride (prescription only, licensed for men): A 5-alpha reductase inhibitor that reduces dihydrotestosterone (DHT) levels, slowing pattern hair loss. It is not licensed for use in women of childbearing potential due to teratogenic risk, and women who are pregnant or may become pregnant must not handle crushed or broken tablets. The MHRA has issued Drug Safety Updates highlighting risks of persistent sexual dysfunction (including after stopping treatment) and psychiatric effects including depression and, rarely, suicidal ideation. Patients should be counselled about these risks before starting treatment; refer to the current MHRA Drug Safety Update and SmPC for full prescribing information.

For alopecia areata, treatment options available through the NHS may include potent topical corticosteroids, intralesional steroid injections, or — in more extensive cases — immunotherapy. NICE Technology Appraisal TA878 (2023) recommended baricitinib (Olumiant®), a JAK inhibitor, as an option for severe alopecia areata in adults within its licensed indication. Baricitinib must be initiated and supervised by a specialist with experience in managing alopecia areata; monitoring requirements apply as set out in the SmPC and NICE guidance.

For hair loss related to nutritional deficiencies, correcting the underlying deficiency through dietary changes or supplementation is the primary intervention. Deficiencies should be confirmed through blood testing before commencing supplementation, as excessive intake of certain nutrients (such as vitamin A or selenium) can itself contribute to hair shedding.

For women with androgenetic alopecia who do not respond to minoxidil, off-label use of spironolactone is sometimes considered under specialist supervision; this should be clearly discussed as off-label prescribing with appropriate counselling.

Always discuss treatment options with your GP or a qualified dermatologist before beginning any new regimen. The BNF, relevant SmPCs, and NHS treatment pages provide authoritative, up-to-date information on licensed indications, dosing, cautions, and contraindications.

Frequently Asked Questions